2025 LISSSD 2025 - 28 articles
Brisbane, Australia | 1–5 June 2025
Volume Editors:
Manisha Pandey, Griffith University, Australia
Michael F. Good, Griffith University, Australia
Joshua Osowicki, Murdoch Children's Research Institute, Australia
Theresa Lamagni, UK Health Security Agency, UK
Associate Editors:
Victoria Ozberk, Griffith University, Australia
Ailin Lepletier, Griffith University, Australia
Rates of acute rheumatic fever (ARF) and rheumatic heart disease (RHD) among New Zealand Māori and Pacific are among the highest reported in high-income countries [...]
There is current interest in the group A streptococcal carbohydrate as a vaccine antigen, and previous studies have suggested that it may induce host tissue cross-reactive autoantibodies which react with heart and brain autoantigens and which are pre...
We identified minimal conserved epitopes on the M-protein (J8, P*17) and the anti-neutrophil chemoattractant virulence factor, SpyCEP (K4S2), of Streptococcus pyogenes (‘Strep A’) as targets of protective antibodies [...]
Background: Rheumatic heart disease (RHD) continues to disproportionately affect young Māori and Pacific Peoples in Aotearoa New Zealand (NZ) [...]
Quorum sensing is a density-dependent form of communication in bacteria [...]
Background: ‘Check4Strep’ is a community-based, participatory action research (PAR) pilot study in a remote northern territory community [...]
Background: Pericardial effusion in ARF has been described in 5–10% of patients, but contemporary data is sparse [...]
Acute rheumatic fever is an autoimmune inflammatory reaction to Streptococcus pyogenes infections, leading to progressive heart valve damage and rheumatic heart disease (RHD) [...]
The high antigenic diversity of Streptococcus pyogenes (StrepA) presents extensive challenges to vaccine development; however, cryptic epitopes—conserved across emm types—offer an alternative approach [...]
Aim: The aim of this study is to assess the impact of COVID-19 on the incidence and molecular epidemiology of invasive infections caused by Streptococcus pneumoniae (IPD) and Streptococcus pyogenes (iGAS) in the Czech Republic (CR) [...]
Despite the substantial burden of Streptococcus pyogenes infections and their associated sequalae, there is currently no Strep A vaccine [...]
Streptococcus pyogenes (Group A Streptococcus, GAS) is an enigmatic human-restricted pathobiont, capable of both colonization and infection [...]
Background: Indigenous communities are disproportionately affected by group A Streptococcus (GAS) infections [...]
Background: Acute rheumatic fever (ARF) is a significant public health concern in resource-limited settings, but its clinical presentation remains inadequately described [...]
Background: The antigenic heterogeneity of GAS poses a challenge for vaccine design [...]
Rheumatic heart disease (RHD), a complication of untreated Strep A infections, is a major global health concern [...]
In 2013, the framework ‘Tools for Implementing Rheumatic Heart Disease (RHD) Control Programmes’ (TIPs) was published [...]
Background [...]
Background/Purpose: Pacific leaders have articulated addressing rheumatic heart disease (RHD) as a Pacific health priority [...]
Streptococcus oralis is an alpha-hemolytic, Gram-positive bacterium from the viridans group streptococci (VGS) [...]
The significant genetic diversity among Group A Streptococcal (GAS) strains isolated from various geographical regions presents serious challenges for treatment and vaccine development strategies [...]
Rheumatic heart disease (RHD) is a devastating consequence of group A streptococcus (StrepA) infections, being associated with 15 [...]
Invasive Group A Streptococcal infection (iGAS) is an uncommon but serious infection with reported case fatality rates of up to 15% [...]
Intro: The epidemiology of invasive group A Streptococcus (iGAS) has been previously documented in Alberta, Canada; however, the role coinfections with respiratory viral infections (VRIs) play with associated emm types remains unclear [...]
Streptococcus pyogenes (Group A Streptococcus, StrepA) is a human pathogen responsible for hundreds of millions of infections each year and remains one of the most prevalent bacterial causes of upper respiratory and skin infections worldwide [...]
Post-streptococcal glomerulonephritis (PSGN) is an immune-mediated kidney disease that occurs after infection with Streptococcus pyogenes (Group A Streptococcus, GAS) [...]
Streptococcus pyogenes can cause a wide variety of acute infections throughout the body of its human host [...]
Background: Group A Streptococcus (GAS) leads to an estimated 600,000 deaths and 600 million cases of pharyngitis per year [...]
Get Alerted
Add your email address to receive forthcoming issues of this journal.
